Table 2.
Short term outcomes and stroke performance metrics in ischemic stroke patients: the 2019 GWTG-Stroke sample and the entire U.S. based on the Bayesian weighted sample.
| Variable | GWTG-Stroke | U.S. 2019 (Bayesian Weighted) |
|---|---|---|
| N=414,628 | N=552,476 N (Proportion, 95% CI) |
|
| Short term outcomes | ||
| Length of stay, days, median (IQR) | 4 (2 – 6) | 4 (2 – 6) |
| Discharge Disposition | ||
| Home | 204,586 (49.3%) | 275,033 (49.8%, 95% CI 49.4–50.1%) |
| Home Hospice | 6,568 (1.6%) | 8,526 (1.5%, 95% CI 1.4–1.7%) |
| Hospice Facility | 12,727 (3.1%) | 16,987 (3.1%, 95% CI 3.0–3.2%) |
| Acute Care Facility | 9,758 (2.4%) | 15,009 (2.7%, 95% CI 2.5–2.9%) |
| Other Health Care Facility | 159,492 (38.5%) | 208,289 (37.7%, 95% CI 37.4–38.0%) |
| Expired | 16,530 (4.0%) | 21,908 (4.0%, 95% CI 3.8–4.1%) |
| Left Against Medical Advice | 4,292 (1.0%) | 5,650 (1.0%, 95% CI 1.0–1.1%) |
| If “Other Health Care Facility” | ||
| Skilled Nursing Facility | 70,714 (44.4%) | 91,998 (44.3%, 95% CI 43.7–44.8%) |
| Inpatient Rehabilitation Facility | 82,889 (52.1%) | 107,735 (51.9%, 95% CI 51.3–52.4%) |
| Long Term Care Hospital | 3,274 (2.1%) | 4,624 (2.2%, 95% CI 2.1–2.4%) |
| Intermediate Care facility | 952 (0.6%) | 1,370 (0.7%, 95% CI 0.6–0.8%) |
| Other | 1,316 (0.8%) | 2,067 (1.0%, 95% CI 0.9–1.1%) |
| Thrombolytic Complications – Symptomatic intracranial hemorrhage <36 hours | 3,316 (3.8%) | 4,263 (3.7%, 95% CI 3.6–3.9%) |
| Discharge ambulatory status | ||
| Unable to ambulate | 46,481 (12.3%) | 62,652 (12.5%, 95% CI 12.3–12.8%) |
| With assistance from person | 118,271 (31.2%) | 154,188 (30.8%, 95% CI 30.5–31.2%) |
| Able to ambulate independently | 197,933 (52.2%) | 261,561 (52.3%, 95% CI 51.9–52.7%) |
| Modified Rankin Scale at Discharge Total, median (IQR) | 3 (1 – 4) | 3 (1 – 4) |
| Achievement Measures | ||
| Acute - IV Thrombolytics Arrive by 2 Hours, Treat by 3 Hours | 30,584 (83.8%) | 38,980 (81.9%, 95% CI 80.7–83.1%) |
| Acute - Early Antithrombotics | 238,022 (97.0%) | 315,212 (96.9%, 95% CI 96.7–97.0%) |
| Acute - VTE Prophylaxis | 302,435 (99.2%) | 398,744 (99.2%, 95% CI 99.1–99.3%) |
| At or by discharge - Antithrombotics | 340,563 (99.2%) | 450,912 (98.9%, 95% CI 98.7–99.0%) |
| At or by discharge - Anticoagulation for Atrial Fibrillation/Flutter | 55,552 (97.2%) | 71,710 (96.9%, 95% CI 96.5–97.4%) |
| At or by discharge - Smoking Cessation | 65,657 (97.9%) | 88,352 (97.2%, 95% CI 96.6–97.8%) |
| At or by discharge - Statin Prescribed at Discharge | 250,031 (98.9%) | 328,842 (98.7%, 95% CI 98.7–98.9%) |
| GWTG/PAA Defect-free Measure | 363,743 (94.3%) | 480,112 (93.7%, 95% CI 93.4–93.9%) |
| Quality Measures | ||
| Acute - Dysphagia Screen | 316,185 (85.8%) | 415,863 (84.9%, 95% CI 84.5–85.2%) |
| Acute - Time to Intravenous Thrombolytic Therapy – 60 minutes | 30,131 (86.3%) | 38,045 (85.0%, 95% CI 83.8–86.1%) |
| Acute - IV Thrombolytics Arrive by 3.5 Hours, Treat by 4.5 Hours | 40,715 (81.3%) | 52,199 (79.7%, 95% CI 78.8–80.7%) |
| Acute - NIHSS Reported | 353,181 (93.8%) | 466,975 (92.9%, 95% CI 92.5–93.2%) |
| At or by discharge - Stroke Education | 192,279 (95.8%) | 256,626 (95.2%, 95% CI 94.8–95.5%) |
| At or by discharge - Rehabilitation Considered | 347,797 (99.0%) | 460,709 (98.8%, 95% CI 98.7–98.9%) |
| At or by discharge - LDL Documented | 325,527 (93.5%) | 429,722 (93.1%, 95% CI 92.8–93.3%) |
| At or by discharge - Intensive Statin Therapy | 130,069 (81.2%) | 173,858 (80.6%, 95% CI 80.1–81.0%) |
| Additional Metrics | ||
| Door to CT time, min, median (IQR) | 33 (13 – 87) | 32 (13 – 86) |
| IV Thrombolytic use | 47,292 (11.4%) | 60,510 (11.0%, 95% CI 10.8–11.1%) |
| Door to IV thrombolytic time, min, median (IQR) | 49 (35 – 68) | 49 (35 – 69) |
| Endovascular treatment use | 29,939 (7.2%) | 39,008 (7.1%, 95% CI 6.9–7.2%) |
| Door to endovascular treatment time, min, median (IQR) | 87 (53 – 128) | 86 (53 – 127) |
VTE = venous thromboembolism, GWTG/PAA = Get With The Guideline / Performance Achievement Award, NIHSS = NIH Stroke Scale/Score